Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

The stock's fall snapped a four-day winning streak.

My name is Will Pickering. I cover U.S. Biotech at Bernstein. I am privileged to be joined today by Vertex's CEO, Reshma Kewalramani. And Reshma, welcome. Sure. Sounds good. Well, good morning ...

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which a week ago released some disappointing quarterly results that could have a notable impact on how ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a ...

It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which a week ago released some disappointing quarterly results that could have a notable impact on how the ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) shares gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings.

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06 ...